Efficacy and immune-related adverse events of ipilimumab and nivolumab combination therapy for a vaginal malignant melanoma

被引：0
|
作者：
Mitsutake, Yano [1 ]
Kota, Konishi [1 ]
Mamiko, Okamoto [1 ]
Kaei, Nasu [1 ,2 ]
机构：
[1] Oita Univ, Dept Obstet & Gynecol, Fac Med, Oita, Japan
[2] Oita Univ, Div Obstet & Gynecol, Support Syst Community Med, Fac Med, Oita, Japan
来源：
JOURNAL OF REPRODUCTIVE IMMUNOLOGY | 2022年 / 153卷
关键词：
D O I：
10.1016/j.jri.2022.103728
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
OP-22
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Correlation between immune-related adverse events and outcomes in nivolumab/ipilimumab combination therapy for metastatic melanoma
    Rauwerdink, Daan
    Frederick, Dennie T.
    Sharova, Tatyana
    Marie, Genevieve
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [2] Nivolumab in melanoma: immune-related adverse events and efficacy
    Reactions Weekly, 2019, 1735 (1) : 11 - 11
  • [3] Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma
    Mehta, Anurag
    Gupta, Arjun
    Hannallah, Franck
    Koshy, Thomas
    Reimold, Sharon
    MELANOMA RESEARCH, 2016, 26 (03) : 319 - 320
  • [4] Ipilimumab and nivolumab induced immune-related adverse events in metastatic mucosal melanoma
    Cao, Yenong
    Afzal, Muhammad Zubair
    Shirai, Keisuke
    BMJ CASE REPORTS, 2021, 14 (08)
  • [5] Role of nivolumab maintenance therapy in advanced melanoma patients following severe immune-related adverse events from combination nivolumab and ipilimumab.
    Maloney, Anna
    Giobbie-Hurder, Anita
    Fogarasi, Miklos C.
    Ott, Patrick Alexander
    Hodi, F. Stephen
    Sussman, Tamara A.
    Silk, Ann W.
    Haq, Rizwan
    Liu, David
    Insco, Megan Leigh
    Buchbinder, Elizabeth Iannotti
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] THE EFFECT OF CANNABIS CONSUMPTION ON IMMUNE RELATED ADVERSE EVENTS IN MELANOMA PATIENTS TREATED WITH IPILIMUMAB NIVOLUMAB COMBINATION THERAPY
    Silman, Yael Steinberg
    Eshet, Lia
    Kennett, Ron
    ben Ami, Sarah
    ONCOLOGY NURSING FORUM, 2021, 48 (02)
  • [7] Early tumour response assessment may avoid serious immune-related adverse events in nivolumab and ipilimumab combination therapy for stage IV melanoma
    Maeda, T.
    Hiura, A.
    Uehara, J.
    Toyoshima, R.
    Nakagawa, T.
    Yoshino, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (03) : 587 - 588
  • [8] Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
    Zhou, Shi
    Khanal, Samrat
    Zhang, Haijun
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 211 - 221
  • [9] Immune-related pancytopenia caused by nivolumab and ipilimumab combination therapy for unresectable melanoma of unknown primary
    Uehara, Jiro
    Yoshino, Koji
    Sugiyama, Eiki
    Ohkuma, Kaori
    Oaku, Satoe
    Yamashita, Chisato
    Hiura, Azusa
    Fujisawa, Yasuhiro
    JOURNAL OF DERMATOLOGY, 2020, 47 (06): : E237 - E239
  • [10] Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis
    Almutairi, Abdulaali R.
    McBride, Ali
    Slack, Marion
    Erstad, Brian L.
    Abraham, Ivo
    FRONTIERS IN ONCOLOGY, 2020, 10
12345